Skip to content
lifestyle.washingtonguardian.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
SHY Therapeutics
SHY Therapeutics Announces the First Patient Has Been Dosed in Phase 1 Clinical Trial Evaluating SHY-ONC6, a Novel, Oral Proteasome Inhibitor for the Treatment of Solid Tumors
August 4, 2026